PINK
Simplify Health Care ETF
PINK is an actively managed fund of US healthcare stocks and/or ETFs. The fund seeks long-term capital growth and commits to donate its net profit, in the form of its annual management fee to the Susan G. Komen Breast Cancer Foundation.
US
EQUITY
Active
MANAGEMENT STYLE
356.8 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Fund sponsor | Simplify Asset Management Inc. |
| Category | US |
| Asset class | Equity |
| Website | link... |
| Inception date | Oct 07, 2021 |
| Assets (mns) | $357 |
| Expense ratio | 50 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | Annually |
| Taxation | 1099 |
| Stock selection | Proprietary |
| Weighting | Proprietary |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| UNITEDHEALTH GROUP INC | 9.3 % |
| ELI LILLY & CO | 8.6 % |
| REGENERON PHARMACEUTICALS | 7.4 % |
| AMGEN INC | 4.9 % |
| ALIGN TECHNOLOGY INC | 4.8 % |
| PURECYCLE TECHNOLOGIES INC | 4.8 % |
| APELLIS PHARMACEUTICALS, INC. | 3.9 % |
| JAZZ PHARMACEUTICALS PLC | 3.5 % |
| UNITED THERAPEUTICS CORP | 3.3 % |
| BIOHAVEN LTD NPV | 3.2 % |
Constituent Breakdown
| Number of holdings | 61 |
| Herfindahl-Hirschman Index | 431 |
| Wgt avg mkt cap (mns) | $187,794 |
| Large cap (>$10bn) | 70.5% |
| Mid cap ($2-10bn) | 15.7% |
| Small cap (<$2bn) | 10.6% |
| Developed mkts. | 97.1% |
| Emerging mkts. | 0.0% |
Country Exposure
 |
UNITED STATES | 84.0 % |
 |
IRELAND | 3.5 % |
 |
BRITAIN | 1.9 % |
 |
COSTA RICA | 1.5 % |
 |
NETHERLANDS | 0.8 % |
Historical Performance
Standardized Performance (as of 12/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 23.4% | 23.4% | 15.7% | 11.2% | -- | -- | -- | 9.4% |
| Dividend Yield | 0.9% | 0.9% | 0.6% | 0.8% | -- | -- | -- | 0.5% |
| Total Returns | 24.3% | 24.3% | 16.3% | 12.0% | -- | -- | -- | 9.9% | Ann. Volatility | 19.2% | 19.2% | 16.9% | 15.9% | -- | -- | -- | 17.3% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.63 | 40% |
| MSCI EAFE | 0.74 | 40% |
| MSCI Emg Mkts | 0.58 | 28% |
Liquidity Measures
| Avg. volume (000) | 162 |
| ADV traded (mns) | $6 |
| Turnover | 1.7% |
| Avg. Bid/Ask (% of price) | 0.10% |
Technical Indicators
| 30d moving avg. (EMA) | $36.74 |
| Relative strength (RSI) | 64 |
| MACD/Signal | 0.42/0.38 |
| Bollinger Bands (Upper/Lower) | $37.97/$36.09 |
| Short interest (% of AUM) | 1.5% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PINK |
Expenses vs. PINK |
ALTAR Score™ vs. PINK |
|---|---|---|---|---|
| XLV | The Health Care Select Sector SPDR Fund | 36.4% | -42 bp | +6.5% |
| IYH | iShares U.S. Healthcare ETF | 35.9% | -10 bp | +5.8% |
| VHT | Vanguard Health Care ETF | 35.7% | -41 bp | +5.1% |
| FHLC | Fidelity MSCI Health Care Index ETF | 35.7% | -42 bp | +5.4% |
| HRTS | Tema Heart & Health ETF | 32.1% | +25 bp | +2.8% |
| IXJ | iShares Global Healthcare ETF | 31.2% | -8 bp | +6.2% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 25.6% | +10 bp | +7.6% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 25.0% | -10 bp | +6.5% |
| LVDS | JPMorgan Fundamental Data Science Large Value ETF | 24.9% | -1 bp | +6.0% |
| PJP | Invesco Pharmaceuticals ETF | 24.8% | +7 bp | +7.5% |
Risk and Returns: PINK vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 1/11/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
AVOID
Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may be less relevant.
ALTAR Score™
PINK
1.4%
Cat. Avg
5.5%
ALTAR Score™ Calculation
Category Overview
There are 1045 funds in the US Equity category, with an average ALTAR Score™
of 5.5% and a standard deviation of
2.2%. PINK's ALTAR Score™ is approximately
1.9 standard deviations
below
the category average. This places PINK in the 3rd percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
PINKSELL
U/W
HOLD
O/W
BUY